- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00764790
Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children
Immunogenicity and Safety of GSK Biologicals' Thimerosal-free TIV Flu Vaccine Versus a Licensed Comparator in Children
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
-
Pokfulam, Hong Kong
- GSK Investigational Site
-
Shatin, Hong Kong
- GSK Investigational Site
-
-
-
-
-
Mexico, Mexique, 6720
- GSK Investigational Site
-
Mexico city, Mexique, 04530
- GSK Investigational Site
-
-
-
-
-
Taipei, Taïwan, 104
- GSK Investigational Site
-
Taipei, Taïwan
- GSK Investigational Site
-
-
-
-
-
Bangkok, Thaïlande, 10400
- GSK Investigational Site
-
-
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35244
- GSK Investigational Site
-
Birmingham, Alabama, États-Unis, 35205
- GSK Investigational Site
-
Dothan, Alabama, États-Unis, 36305
- GSK Investigational Site
-
-
Arkansas
-
Benton, Arkansas, États-Unis, 72019
- GSK Investigational Site
-
Conway, Arkansas, États-Unis, 72034
- GSK Investigational Site
-
Fayetteville, Arkansas, États-Unis, 72703
- GSK Investigational Site
-
Jonesboro, Arkansas, États-Unis, 72401
- GSK Investigational Site
-
Little Rock, Arkansas, États-Unis, 72205
- GSK Investigational Site
-
-
California
-
Huntington Beach, California, États-Unis, 92647
- GSK Investigational Site
-
Long Beach, California, États-Unis, 90806
- GSK Investigational Site
-
Paramount, California, États-Unis, 90723
- GSK Investigational Site
-
Sacramento, California, États-Unis, 95816
- GSK Investigational Site
-
San Francisco, California, États-Unis, 94102
- GSK Investigational Site
-
West Covina, California, États-Unis, 91790
- GSK Investigational Site
-
-
Colorado
-
Longmont, Colorado, États-Unis, 80501
- GSK Investigational Site
-
-
Connecticut
-
Norwich, Connecticut, États-Unis, 06360
- GSK Investigational Site
-
-
Idaho
-
Nampa, Idaho, États-Unis, 83686
- GSK Investigational Site
-
-
Illinois
-
DeKalb, Illinois, États-Unis, 60115
- GSK Investigational Site
-
-
Indiana
-
New Albany, Indiana, États-Unis, 47150
- GSK Investigational Site
-
-
Kansas
-
Arkansas City, Kansas, États-Unis, 67005
- GSK Investigational Site
-
Newton, Kansas, États-Unis, 67114
- GSK Investigational Site
-
Wichita, Kansas, États-Unis, 67207
- GSK Investigational Site
-
-
Kentucky
-
Bardstown, Kentucky, États-Unis, 40004
- GSK Investigational Site
-
Louisville, Kentucky, États-Unis, 40207
- GSK Investigational Site
-
-
Louisiana
-
Bossier City, Louisiana, États-Unis, 71111
- GSK Investigational Site
-
Metairie, Louisiana, États-Unis, 70006
- GSK Investigational Site
-
-
Michigan
-
Stevensville, Michigan, États-Unis, 49127
- GSK Investigational Site
-
-
Minnesota
-
Saint Paul, Minnesota, États-Unis, 55108
- GSK Investigational Site
-
-
Missouri
-
Saint Louis, Missouri, États-Unis, 63141
- GSK Investigational Site
-
-
Nebraska
-
Omaha, Nebraska, États-Unis, 68134
- GSK Investigational Site
-
-
Nevada
-
Henderson, Nevada, États-Unis, 89015
- GSK Investigational Site
-
-
New York
-
Cortland, New York, États-Unis, 13045
- GSK Investigational Site
-
-
North Carolina
-
Boone, North Carolina, États-Unis, 28607
- GSK Investigational Site
-
Cary, North Carolina, États-Unis, 27518
- GSK Investigational Site
-
Raleigh, North Carolina, États-Unis, 27609
- GSK Investigational Site
-
-
North Dakota
-
Fargo, North Dakota, États-Unis, 58103
- GSK Investigational Site
-
-
Ohio
-
Austintown, Ohio, États-Unis, 44515
- GSK Investigational Site
-
Cincinnati, Ohio, États-Unis, 45245
- GSK Investigational Site
-
Cleveland, Ohio, États-Unis, 44121
- GSK Investigational Site
-
Dayton, Ohio, États-Unis, 45406
- GSK Investigational Site
-
-
Oregon
-
Gresham, Oregon, États-Unis, 97030
- GSK Investigational Site
-
-
Pennsylvania
-
Erie, Pennsylvania, États-Unis, 16505
- GSK Investigational Site
-
Greenville, Pennsylvania, États-Unis, 16125
- GSK Investigational Site
-
Latrobe, Pennsylvania, États-Unis, 15650
- GSK Investigational Site
-
Pittsburgh, Pennsylvania, États-Unis, 15236
- GSK Investigational Site
-
Uniontown, Pennsylvania, États-Unis, 15401
- GSK Investigational Site
-
Wexford, Pennsylvania, États-Unis, 15090
- GSK Investigational Site
-
-
South Carolina
-
Charleston, South Carolina, États-Unis, 29406
- GSK Investigational Site
-
-
Tennessee
-
Clarksville, Tennessee, États-Unis, 37043
- GSK Investigational Site
-
Jackson, Tennessee, États-Unis, 38305
- GSK Investigational Site
-
Kingsport, Tennessee, États-Unis, 37660
- GSK Investigational Site
-
-
Texas
-
Austin, Texas, États-Unis, 78705
- GSK Investigational Site
-
Fort Worth, Texas, États-Unis, 76135
- GSK Investigational Site
-
Houston, Texas, États-Unis, 77055
- GSK Investigational Site
-
San Angelo, Texas, États-Unis, 76904
- GSK Investigational Site
-
-
Utah
-
Bountiful, Utah, États-Unis, 84010
- GSK Investigational Site
-
Layton, Utah, États-Unis, 84041
- GSK Investigational Site
-
Murray, Utah, États-Unis, 84107
- GSK Investigational Site
-
Provo, Utah, États-Unis, 84604
- GSK Investigational Site
-
Roy, Utah, États-Unis, 84067
- GSK Investigational Site
-
South Jordan, Utah, États-Unis, 84095
- GSK Investigational Site
-
-
Virginia
-
Burke, Virginia, États-Unis, 22015
- GSK Investigational Site
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- A male or female child aged 6 to 35 months at the time of the first vaccination; children who may or may not have had previous administration of influenza vaccine in a previous season are acceptable.
- Subjects having a parent/guardian who the investigator believes can and will comply with the requirements of the protocol.
- Written informed consent obtained from the subject's parent/guardian.
Exclusion Criteria:
- Use of any investigational or non-registered product (drug or vaccine) within 30 days preceding the administration of the study vaccine, or planned use during the study period. Routine, registered childhood vaccinations are not an exclusion criterion.
- History of hypersensitivity to any vaccine.
- History of allergy or reactions likely to be exacerbated by any component of the vaccine.
- Acute disease at the time of enrolment.
- History of Guillain Barré syndrome within 6 weeks of receipt of prior inactivated influenza virus vaccine.
- Receipt of an influenza vaccine outside of this study, during current (2008-09) flu season.
- Administration of immunoglobulins and/or blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Fluarix Dose A Group
Subjects were administered 1 or 2 doses* of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age). * Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses. |
One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection.
Two different doses are tested.
|
|
Expérimental: Fluarix Dose B Group
Subjects were administered 1 or 2 doses*, half the volume of dose A, of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age). * Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses. |
One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection.
Two different doses are tested.
|
|
Comparateur actif: Fluzone Group
Subjects were administered 1 or 2 doses* of Fluzone vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age). * Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses. |
One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Geometric Mean Titer (GMT) of Serum Anti-hemagglutinin (HA) Antibodies Against Each of the Influenza Vaccine Strains
Délai: Day 0 (PRE), Day 28 or Day 56 (POST)
|
GMTs and their 95% confidence interval are presented for all 3 viral strains comprised in the vaccine. Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects |
Day 0 (PRE), Day 28 or Day 56 (POST)
|
|
Number of Subjects Who Seroconverted
Délai: Day 28 or Day 56
|
Seroconversion is defined as the number of subjects with either a pre-vaccination anti-HA titer < 1:10 and a post-vaccination titer ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and a minimum 4-fold increase at post-vaccination titer. Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects |
Day 28 or Day 56
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of Seroprotected Subjects
Délai: Day 0 (PRE), Day 28 or Day 56 (POST)
|
A seroprotected subject is a subject with a serum anti-HA titer ≥ 1:40 Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects |
Day 0 (PRE), Day 28 or Day 56 (POST)
|
|
Seroconversion Factor
Délai: Day 28 or Day 56
|
Seroconversion factor is defined as the fold increase in serum anti-HA GMTs post-vaccination (Day 28 or 56) compared to pre-vaccination (Day 0). Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects |
Day 28 or Day 56
|
|
Number of Subjects Reporting Solicited Local Symptoms
Délai: During a 4-day follow-up period after vaccination
|
Solicited local symptoms assessed include pain, redness and swelling.
|
During a 4-day follow-up period after vaccination
|
|
Number of Subjects Reporting Solicited General Symptoms
Délai: During a 4-day follow-up period after vaccination
|
Solicited general symptoms assessed include drowsiness, irritability, loss of appetitie, and temperature.
|
During a 4-day follow-up period after vaccination
|
|
Number of Subjects Reporting Unsolicited Adverse Events (AE)
Délai: During a 28-day follow-up period after vaccination
|
An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product
|
During a 28-day follow-up period after vaccination
|
|
Number of Subjects Reporting Serious Adverse Events (SAE) and New Onset of Chronic Diseases (NOCD)
Délai: During the entire study (Day 0 until Month 6)
|
An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above. NOCDs assessed include for example: diabetes, asthma, allergies, autoimmune disease, cancer, neuropathic disorders |
During the entire study (Day 0 until Month 6)
|
|
Number of Subjects Reporting Rare Serious Events
Délai: During the entire study (Day 0 until Month 6)
|
Rare serious events have an occurrence rate of 1/300 (0.3%).
|
During the entire study (Day 0 until Month 6)
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Publications générales
- Li-Kim-Moy J, Wood N, Jones C, Macartney K, Booy R. Impact of Fever and Antipyretic Use on Influenza Vaccine Immune Reponses in Children. Pediatr Infect Dis J. 2018 Oct;37(10):971-975. doi: 10.1097/INF.0000000000001949.
- Pavia-Ruz N, Angel Rodriguez Weber M, Lau YL, Nelson EA, Kerdpanich A, Huang LM, Silas P, Qaqundah P, Blatter M, Jeanfreau R, Lei P, Jain V, El Idrissi M, Feng Y, Innis B, Peeters M, Devaster JM. A randomized controlled study to evaluate the immunogenicity of a trivalent inactivated seasonal influenza vaccine at two dosages in children 6 to 35 months of age. Hum Vaccin Immunother. 2013 Sep;9(9):1978-88. doi: 10.4161/hv.25363. Epub 2013 Jun 19.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 111751
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Données/documents d'étude
-
Spécification du jeu de données
Identifiant des informations: 111751Commentaires d'informations: For additional information about this study please refer to the GSK Clinical Study Register
-
Formulaire de consentement éclairé
Identifiant des informations: 111751Commentaires d'informations: For additional information about this study please refer to the GSK Clinical Study Register
-
Plan d'analyse statistique
Identifiant des informations: 111751Commentaires d'informations: For additional information about this study please refer to the GSK Clinical Study Register
-
Formulaire de rapport de cas annoté
Identifiant des informations: 111751Commentaires d'informations: For additional information about this study please refer to the GSK Clinical Study Register
-
Rapport d'étude clinique
Identifiant des informations: 111751Commentaires d'informations: For additional information about this study please refer to the GSK Clinical Study Register
-
Ensemble de données de participant individuel
Identifiant des informations: 111751Commentaires d'informations: For additional information about this study please refer to the GSK Clinical Study Register
-
Protocole d'étude
Identifiant des informations: 111751Commentaires d'informations: For additional information about this study please refer to the GSK Clinical Study Register
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .